Introduction
============

Hepatocellular carcinoma (HCC) is the fifth most common malignancy and arises most frequently in patients with cirrhosis ([@b1-ol-0-0-8552]). It is the second most common cause of cancer-associated mortality globally with 1.6 million mortalities per year, and it is hypothesized that the high global incidence rate and late presentation of HCC may be responsible for this ([@b2-ol-0-0-8552],[@b3-ol-0-0-8552]). Additionally, the general prognosis was poor with an overall survival rate between 3 and 5% in 2006 ([@b4-ol-0-0-8552]). Symptoms of HCC include yellow skin, bloating from fluid in the abdomen, easy bruising from blood clotting abnormalities, loss of appetite, unintentional weight loss, nausea, vomiting and tiredness ([@b5-ol-0-0-8552],[@b6-ol-0-0-8552]). The primary risk factors for HCC were hepatitis C, hepatitis B, alcoholism, aflatoxin and cirrhosis of the liver ([@b7-ol-0-0-8552]--[@b10-ol-0-0-8552]). Liver transplantation, tyrosine kinase inhibitors and surgical resection are currently the primary treatment options ([@b11-ol-0-0-8552]--[@b13-ol-0-0-8552]). The treatment of HCC has not been fundamentally improved, which may be seen in the increasing morbidity and mortality each year ([@b14-ol-0-0-8552]). Ribavirin is an anti-viral drug used to treat hepatitis C, respiratory syncytial virus and other viral infections. If infection is persistent, ribavirin is often used in combination with peginterferon α-2b or peginterferon α-2a ([@b15-ol-0-0-8552],[@b16-ol-0-0-8552]). It has been reported that hepatitis C infection was globally associated with 25% of HCC cases in 2006 ([@b15-ol-0-0-8552]). Therefore, ribavirin, by itself or in conjunction with peginterferon α-2b or pegylated interferon, has been used to treat HCC in patients with viral infections ([@b17-ol-0-0-8552]--[@b20-ol-0-0-8552]). Exploration of the genetic changes in HCC cells is necessary for the study of the pathogenesis and progression of HCC, as well as to develop effective treatments. In the present study, a microarray analysis of mRNA and microRNA (miRNA) was performed in the treatment of ribavirin on HCC, in order to identify possible biomarkers and provide novel potential therapeutic targets for HCC.

Materials and methods
=====================

### Microarray data and data prx10-processing

The mRNA expression datasets of GSE23031 and GSE74656, as well as the miRNA expression dataset of GSE22058, ([@b21-ol-0-0-8552]--[@b23-ol-0-0-8552]) were downloaded from the Gene Expressed Omnibus database (<http://www.ncbi.nlm.nih.gov/geo/>). They were analyzed using the platforms GPL570 \[HG-U133_Plus_2\] Affymetrix Human Genome U133 Plus 2.0 Array (Thermo Fisher Scientific, Inc., Waltham, MA, USA), GPL16043 GeneChip^®^ PrimeView™ Human Gene Expression Array (with External spikx10-in RNAs; Thermo Fisher Scientific, Inc.) and GPL10457 Rosetta human miRNA qPCR array (Rosetta Inpharmatics; Merck Sharp & Dohme, Hoddesdon, UK), respectively. The mRNA data (GSE23031) contained three HCC cell lines treated with PBS and three HCC cell lines treated with ribavirin. In the GSE74656, five HCC tissues and five carcinoma adjacent tissues were selected for the study. In the GSE22058, 96 HCC tissues and 96 carcinoma adjacent tissues were selected to study. Robust Multi-Array Average (RMA) was an algorithm used to create an expression matrix from Affymetrix data ([@b24-ol-0-0-8552]). The raw data were converted into a recognizable format by *R*, and the RMA was used for correction and normalization.

### Differential expression analysis

The differentially expressed genes (DEGs) were identified via the limma package V3.32.10 (<http://www.bioconductor.org/packages/3.5/bioc/html/limma.html>) ([@b25-ol-0-0-8552]). According to the criteria: P\<0.05 and \|log(fold change)\|\>1, the DEGs were identified in HCC cells treated with ribavirin compared with PBS and designated DEG-Ribavirin. With the same criteria, the DEGs were identified in HCC tissues compared with their matched adjacent tissues and designated DEG-Tumor. Additionally, the differentially expressed miRNAs (DEMs) were obtained in HCC tissues compared with carcinoma adjacent tissues with P\<0.05 and \|log(fold change)\|\>0.3.

### Functional and pathway enrichment analysis

The Database for Annotation, Visualization and Integrated Discovery (<https://david.ncifcrf.gov/>) ([@b26-ol-0-0-8552]) is a widely-used web-based tool for functional and pathway enrichment analysis. In the present study, it was used to perform Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis of DEG-Ribavirin and DEG-Tumor data. The GO terms and KEGG pathways were selected with P\<0.05.

### Comparison of DEGs and screening of miRNA-mRNA regulated pairs

The overlapped DEGs of DEG-Ribavirin and DEG-Tumor were selected, and the overlapped DEGs with opposite expression between DEG-Ribavirin and DEG-Tumor were also selected. The TargetScan database was used to predict biological target mRNAs of miRNAs that matched the seed region of each miRNA ([@b27-ol-0-0-8552]). The target mRNAs of DEMs were then selected using TargetScan. The key miRNAs, which regulated the overlapped DEGs with opposite expression between DEG-Ribavirin and DEG-Tumor, were identified. Subsequently, the miRNA-mRNA regulated pairs were constructed.

Results
=======

DEGs. A total of 559 DEGs (269 upregulated and 290 downregulated) and 623 DEGs (272 upregulated and 351 downregulated) were identified in DEG-Ribavirin and DEG-Tumor. The heat map of them and the top 30 most significant DEGs are presented in [Figs. 1](#f1-ol-0-0-8552){ref-type="fig"} and [2](#f2-ol-0-0-8552){ref-type="fig"}, [Tables I](#tI-ol-0-0-8552){ref-type="table"} and [II](#tII-ol-0-0-8552){ref-type="table"}, respectively. A total of 220 DEMs were obtained. The 30 most significant DEMs are presented in [Table III](#tIII-ol-0-0-8552){ref-type="table"}.

### GO terms and KEGG pathways

A total of 121 GO terms and 3 KEGG pathways (cell cycle pathway, p53 signaling pathway and glycine, serine and threonine metabolism pathway) of DEG-Ribavirin were obtained. A total of 383 GO terms and 25 KEGG pathways of DEG-Tumor were obtained. The top 20 enriched GO terms of DEG-Ribavirin and DEG-Tumor are presented in [Tables IV](#tIV-ol-0-0-8552){ref-type="table"} and [V](#tV-ol-0-0-8552){ref-type="table"}, respectively. The enriched KEGG pathways of DEG-Ribavirin and DEG-Tumor are presented in [Tables VI](#tVI-ol-0-0-8552){ref-type="table"} and [VII](#tVII-ol-0-0-8552){ref-type="table"}, respectively.

### miRNA-mRNA regulated pairs

There were 50 overlapped DEGs, with 32 \[including N-acetyltransferase (*NAT2*) and F-box only protein 5 (*FBXO5*)\] exhibiting opposite expression between DEG-Ribavirin, and DEG-Tumor. A heat map of the 32 overlapped DEGs is presented in [Fig. 3](#f3-ol-0-0-8552){ref-type="fig"}. Furthermore, three DEMs (*miR-96, miR-145* and *miR-183*) were revealed to correspond to three DEGs (*CCNB1, DEPDC1* and *NTN4*) which were included in the aforementioned 32 overlapped DEGs. Finally, five miRNA-mRNA regulated pairs were selected between the above three DEGs and the three DEMs, namely *miR-183*→*CCNB1, miR-96*→*DEPDC1, miR-96*→*NTN4, miR-183*→*NTN4* and *miR-145*→*NTN4*.

Discussion
==========

In the present study, the DEGs in HCC cells treated with ribavirin compared with PBS treated HCC tissue, HCC tissues and carcinoma adjacent tissues, were firstly identified, and 32 overlapped DEGs with opposite expression between DEG-Ribavirin and DEG-Tumor were selected. It was notable that *NAT2* and *FBXO5* were two mRNAs of them with opposite expression between DEG-Ribavirin and DEG-Tumor. NAT2 serves a function in the metabolic activation and detoxification of aromatic amines, which in turn serves a function in the metabolism of aromatic and heterocyclic amines, and hydrazines via N-acetylation and O-acetylation ([@b28-ol-0-0-8552]). As early as in 1996, Agúndez *et al* ([@b29-ol-0-0-8552]) reported that the slow acetylation was associated with an increased risk of HCC. Furthermore, it has been demonstrated that *NAT2* activity is associated with smoking-associated HCC ([@b30-ol-0-0-8552]--[@b32-ol-0-0-8552]). A number of previous studies that have investigated the association between *NAT2* genotypes and HCC risk have been published ([@b32-ol-0-0-8552]--[@b36-ol-0-0-8552]). *FBXO5*, also known as early mitotic inhibitor-1, is a key cell-cycle regulator that promotes S-phase and M-phase entry by inhibiting anaphasx10-promoting complex/cyclosome activity ([@b37-ol-0-0-8552]). Zhao *et al* ([@b38-ol-0-0-8552]) revealed that *FBXO5* was overexpressed in HCC, which is in agreement with the results of the present study, and also reported that *FBXO5* may control tumor cell proliferation in HCC. In the present study, it was identified that the expression of *NAT2* was lower in HCC cells and HCC tissues. However, expression was increased following treatment with ribavirin. However, *FBXO5* was overexpressed in HCC cells and HCC tissues, and decreased following treatment with ribavirin. Therefore, it is suspected that *NAT2* and *FBXO5* may be biomarkers of ribavirin in the treatment of HCC.

The cell cycle has been demonstrated to be associated with the progression and migration of HCC ([@b39-ol-0-0-8552]--[@b41-ol-0-0-8552]), and regulation of the cell cycle is considered an effective strategy for HCC treatment ([@b42-ol-0-0-8552]--[@b45-ol-0-0-8552]). The p53 signaling pathway has been heavily studied and is reported to serve a function in the occurrence and development of HCC ([@b45-ol-0-0-8552]--[@b49-ol-0-0-8552]). The association between the glycine, serine and threonine metabolism pathway and HCC has been less studied, and the glycine, serine and threonine metabolism pathway was also enriched in DEG-Tumor tissues. In this study, only three KEGG pathways of DEG-Ribavirin were obtained, namely cell cycle, p53 signaling pathway and glycine, serine and threonine metabolism. Cell cycle was the most significantly enriched function in this study, which was identified from the enriched GO terms of DEG-Ribavirin (e.g. cell cycle phase, cell cycle and M phase) and DEG-Tumor (e.g. M phase and cell cycle phase), as well as the enriched KEGG pathways of DEG-Tumor. The results of the present study suggest that these three KEGG pathways may be associated with the pathogenesis and treatment of HCC; however, more in-depth research is required.

In the present study, three DEMs (*miR-96, miR-145* and *miR-183*) were identified to correspond to three overlapped DEGs (*CCNB1, DEPDC1* and *NTN4*) with opposite expression in DEG-Ribavirin and DEG-Tumor, and 5 miRNA-mRNA regulated pairs were selected, namely *miR-183*→*CCNB1, miR-96*→*DEPDC1, miR-96*→*NTN4, miR-183*→*NTN4* and *miR-145*→*NTN4*. It has been demonstrated that *miR-96* downregulation may suppress the growth of HCC ([@b50-ol-0-0-8552]), and *miR-96* may promote cell proliferation and invasion through targeting ephrinA5 in HCC ([@b51-ol-0-0-8552]). Chen *et al* ([@b52-ol-0-0-8552]) considered serum *miR-96* as a promising biomarker for HCC with chronic hepatitis B virus infection. Previous studies have demonstrated that *miR-145* may inhibit proliferation, migration and invasion, as well as promote apoptosis in HCC ([@b53-ol-0-0-8552]--[@b56-ol-0-0-8552]). *MiR-183* may also regulate the growth, invasion and apoptosis of HCC ([@b57-ol-0-0-8552]--[@b59-ol-0-0-8552]). It has been identified that these miRNA and mRNA are possible biomarkers of ribavirin in HCC, and they may regulate HCC through the 5 miRNA-mRNA pairs.

In conclusion, a number of miRNAs (e.g. *miR-96, miR-145* and *miR-183*) and mRNAs (e.g. *NAT2, FBXO5, CCNB1, DEPDC1* and *NTN4*) may be associated with the effects of ribavirin on HCC. Furthermore, they may provide novel therapeutic targets for drugs of HCC.
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###### 

Top 30 most significant differentially expressed genes in hepatocellular carcinoma cells treated with ribavirin compared with PBS.

  Gene           logFC      Average expression   P-value
  -------------- ---------- -------------------- --------------
  NCF2           3.636237   10.08812             4.01×10^−13^
  TXNIP          3.04897    9.867782             5.95×10^−12^
  PRORSD1P       2.527183   6.729178             4.91×10^−11^
  NPPB           3.0072     12.09607             8.26×10^−11^
  CYR61          2.018572   10.7489              9.19×10^−11^
  PLA2G4C        1.93915    5.61348              9.29×10^−11^
  CDKN2B         2.282063   7.523593             9.52×10^−11^
  LEAP2          2.52559    9.937438             1.39×10^−10^
  DUSP4          1.86831    8.419143             3.18×10^−10^
  FLVCR1-AS1     2.01682    8.90536              4.17×10^−10^
  ASH1L-AS1      1.803117   9.666342             4.20×10^−10^
  CXCL3          1.797497   8.092698             5.80×10^−10^
  GLIPR2         1.688522   9.089844             5.91×10^−10^
  CYP1A1         1.560867   11.576               7.61×10^−10^
  EID2B          1.667057   8.101158             9.18×10^−10^
  JUNB           1.574027   8.65205              1.10×10^−09^
  BTG2           1.498662   9.091506             1.41×10^−09^
  PPL            1.94965    8.769882             2.08×10^−09^
  ZNF436-AS1     2.570947   8.267133             2.12×10^−09^
  TIGD7          1.654807   6.61165              2.17×10^−09^
  LOC284513      1.59588    6.487373             2.40×10^−09^
  TUFT1          1.50993    10.31677             2.43×10^−09^
  CTSE           1.439267   11.22817             2.48×10^−09^
  ERP27          1.376543   10.6632              2.51×10^−09^
  UCA1           1.611053   10.73581             2.60×10^−09^
  HSD3B1         1.699597   5.372037             2.61×10^−09^
  GATA6-AS1      1.971443   9.336978             2.99×10^−09^
  LOC100134822   1.45604    7.840603             3.38×10^−09^
  THUMPD3-AS1    1.365701   7.84944              3.41×10^−09^
  GDA            1.482742   8.376296             3.62×10^−09^

logFC, log fold-change.

###### 

Top 30 most significant DEGs in HCC tissues compared with carcinoma adjacent tissues.

  Gene       logFC      Average expression   P-value
  ---------- ---------- -------------------- --------------
  CTHRC1     2.856945   5.825291             6.69×10^−07^
  PEA15      1.468145   8.69977              1.04×10^−06^
  CENPE      2.043658   6.056165             1.29×10^−06^
  C21orf56   1.237448   5.670084             1.54×10^−06^
  DBN1       1.383559   6.53977              1.76×10^−06^
  GLA        1.380323   7.172235             2.00×10^−06^
  DDX39      1.17872    7.721654             2.63×10^−06^
  MPV17      1.190142   9.079669             2.67×10^−06^
  RFX5       1.417855   7.558042             2.89×10^−06^
  TMEM144    1.379456   5.655336             3.59×10^−06^
  ASNS       2.515006   6.603396             3.63×10^−06^
  SLC38A6    1.678498   7.591919             3.93×10^−06^
  GRAMD1A    1.013492   7.228709             4.65×10^−06^
  COMMD8     1.109678   8.353807             7.57×10^−06^
  YWHAZ      1.008572   8.92205              7.94×10^−06^
  PLXNC1     1.451381   5.772042             1.18×10^−05^
  PLVAP      1.001818   5.796379             1.20×10^−05^
  SHCBP1     1.327673   4.917339             1.39×10^−05^
  LAMC1      1.104793   6.905647             1.46×10^−05^
  ANXA2P2    1.89594    11.61567             1.52×10^−05^
  ACTR3      1.094921   9.606995             1.63×10^−05^
  CCDC88A    1.002649   6.195715             1.64×10^−05^
  E2F3       1.093946   6.541921             1.75×10^−05^
  FAM118B    1.006248   6.9915               1.76×10^−05^
  ZNF354A    1.069078   5.918941             1.81×10^−05^
  RASGEF1A   2.021872   4.908126             1.84×10^−05^
  NUP37      1.362635   6.839194             2.01×10^−05^
  ESM1       1.291572   4.762991             2.03×10^−05^
  KPNA2      2.606398   9.341649             2.13×10^−05^
  DCUN1D5    1.38889    8.463629             2.34×10^−05^

logFC, log fold-change; HCC, hepatocellular carcinoma; DEGs, differentially expressed genes.

###### 

Top 30 most significant differentially expressed miRNA in HCC tissues compared with carcinoma adjacent tissues.

  miRNA            logFC      P-value
  ---------------- ---------- --------------
  hsa-mir-188      0.36842    2.41×10^−39^
  hsa-mir-106b     0.32071    1.52×10^−36^
  hsa-mir-214      −0.54861   7.34×10^−36^
  hsa-mir-93       0.32346    1.73×10^−35^
  hsa-mir-10a      −0.51702   6.33×10^−35^
  hsa-mir-199a-1   −0.78765   6.28×10^−33^
  hsa-mir-199a-2   −0.73035   5.57×10^−31^
  hsa-mir-301      0.5629     1.16×10^−28^
  hsa-mir-424      −0.31246   1.72×10^−28^
  hsa-mir-33       0.29308    7.92×10^−26^
  hsa-mir-324-5p   0.37868    1.01×10^−23^
  hsa-mir-25       0.20282    1.53×10^−22^
  hsa-mir-125b     −0.37741   1.95×10^−22^
  hsa-mir-339      0.21825    3.36×10^−21^
  hsa-mir-145      −0.35693   4.27×10^−21^
  hsa-mir-148b     0.20955    6.76×10^−21^
  hsa-mir-151      0.25728    9.53×10^−21^
  hsa-mir-221      0.35829    1.39×10^−20^
  hsa-mir-18a      0.41731    3.09×10^−20^
  hsa-mir-130b     0.38724    3.75×10^−20^
  hsa-mir-195      −0.34663   6.72×10^−20^
  hsa-mir-99a      −0.38524   8.55×10^−20^
  hsa-mir-15b      0.27273    1.80×10^−19^
  hsa-mir-183      0.42758    2.31×10^−19^
  hsa-mir-222      0.30098    2.62×10^−18^
  hsa-mir-125a     −0.26924   4.47×10^−18^
  hsa-mir-378      −0.33767   7.60×10^−18^
  hsa-mir-101      −0.24801   1.85×10^−17^
  hsa-mir-331      0.20462    2.33×10^−17^
  hsa-mir-200b     −0.6996    2.38×10^−17^

HCC, hepatocellular carcinoma; logFC, log fold-change; mir, microRNA.

###### 

Top 20 enriched GO terms of DEG-Ribavirin.

  Category   GO ID        Go name                         Gene number   P-value
  ---------- ------------ ------------------------------- ------------- --------------
  BP         GO:0022403   Cell cycle phase                29            1.66×10^−06^
  BP         GO:0007049   Cell cycle                      43            1.66×10^−06^
  BP         GO:0000279   M phase                         24            8.49×10^−06^
  BP         GO:0007067   Mitosis                         19            1.02×10^−05^
  BP         GO:0000280   Nuclear division                19            1.02×10^−05^
  BP         GO:0000087   M phase of mitotic cell cycle   19            1.29×10^−05^
  BP         GO:0048285   Organelle fission               19            1.73×10^−05^
  BP         GO:0000278   Mitotic cell cycle              25            1.88×10^−05^
  BP         GO:0022402   Cell cycle process              32            3.23×10^−05^
  BP         GO:0008283   Cell proliferation              27            3.62×10^−05^
  BP         GO:0031497   Chromatin assembly              11            5.88×10^−05^
  BP         GO:0065004   Protein-DNA complex assembly    11            8.65×10^−05^
  BP         GO:0006334   Nucleosome assembly             10            2.36×10^−04^
  BP         GO:0051726   Regulation of cell cycle        21            2.43×10^−04^
  BP         GO:0051301   Cell division                   19            4.39×10^−04^
  BP         GO:0034728   Nucleosome organization         10            5.08×10^−04^
  BP         GO:0006323   DNA packaging                   11            6.79×10^−04^
  CC         GO:0000786   Nucleosome                        8           9.25×10^−04^
  BP         GO:0010033   Response to organic substance   33            0.001109
  CC         GO:0005819   Spindle                         12            0.001114

GO, Gene Ontology; DEGs, differentially expressed genes; CC, cellular component; BP, biological process.

###### 

Top 20 enriched GO terms of DEG-tumor.

  Category   GO ID        Go name                                    Gene number   P-value
  ---------- ------------ ------------------------------------------ ------------- --------------
  BP         GO:0000279   M phase                                    49            1.22×10^−17^
  BP         GO:0022403   Cell cycle phase                           54            7.41×10^−17^
  BP         GO:0007067   Mitosis                                    39            1.19×10^−16^
  BP         GO:0000280   Nuclear division                           39            1.19×10^−16^
  BP         GO:0000087   M phase of mitotic cell cycle              39            2.21×10^−16^
  BP         GO:0000278   Mitotic cell cycle                         50            4.09×10^−16^
  BP         GO:0048285   Organelle fission                          39            5.79×10^−16^
  BP         GO:0022402   Cell cycle process                         61            5.37×10^−15^
  MF         GO:0048037   Cofactor binding                           39            3.37×10^−14^
  BP         GO:0016054   Organic acid catabolic process             26            4.73×10^−14^
  BP         GO:0046395   Carboxylic acid catabolic process          26            4.73×10^−14^
  CC         GO:0005819   Spindle                                    30            7.20×10^−14^
  BP         GO:0007049   Cell cycle                                 71            9.42×10^−14^
  BP         GO:0055114   Oxidation reduction                        62            3.81×10^−13^
  BP         GO:0007059   Chromosome segregation                     21            2.69×10^−12^
  MF         GO:0009055   Electron carrier activity                  34            3.23×10^−12^
  CC         GO:0000793   Condensed chromosome                       26            5.97×10^−12^
  CC         GO:0000777   Condensed chromosome kinetochore           18            1.41×10^−11^
  MF         GO:0050662   Coenzyme binding                           29            6.32×10^−11^
  CC         GO:0000779   Condensed chromosome, centromeric region   18            1.37×10^−10^

GO, Gene Ontology; DEGs, differentially expressed genes; CC, cellular component; BP, biological process; MF, molecular foundation.

###### 

Enriched KEGG pathways of DEG-Ribavirin.

  Category       Pathway name                                         Gene number   P-value
  -------------- ---------------------------------------------------- ------------- --------------
  KEGG_PATHWAY   hsa04110: Cell cycle                                 15            1.19×10^−05^
  KEGG_PATHWAY   hsa00260: Glycine, serine and threonine metabolism     5           0.011495
  KEGG_PATHWAY   hsa04115: p53 signaling pathway                        6           0.045851

DEGs, differentially expressed genes; KEGG, Kyoto Encyclopedia of Genes and Genomes.

###### 

Enriched KEGG pathways of DEG-tumor.

  Category       Pathway name                                             Gene number   P-value
  -------------- -------------------------------------------------------- ------------- --------------
  KEGG_PATHWAY   hsa00071: Fatty acid metabolism                          15            1.37×10^−09^
  KEGG_PATHWAY   hsa00280: Valine, leucine and isoleucine degradation     14            5.58×10^−08^
  KEGG_PATHWAY   hsa04110: Cell cycle                                     21            1.08×10^−06^
  KEGG_PATHWAY   hsa00830: Retinol metabolism                             12            3.12×10^−05^
  KEGG_PATHWAY   hsa00380: Tryptophan metabolism                          10            7.32×10^−05^
  KEGG_PATHWAY   hsa00650: Butanoate metabolism                             9           1.33×10^−04^
  KEGG_PATHWAY   hsa00250: Alanine, aspartate and glutamate metabolism      8           4.63×10^−04^
  KEGG_PATHWAY   hsa04114: Oocyte meiosis                                 15            5.67×10^−04^
  KEGG_PATHWAY   hsa00640: Propanoate metabolism                            8           5.69×10^−04^
  KEGG_PATHWAY   hsa03320: PPAR signaling pathway                         11            0.001281
  KEGG_PATHWAY   hsa00980: Metabolism of xenobiotics by cytochrome P450   10            0.00174
  KEGG_PATHWAY   hsa00910: Nitrogen metabolism                              6           0.003688
  KEGG_PATHWAY   hsa00590: Arachidonic acid metabolism                      9           0.004249
  KEGG_PATHWAY   hsa00140: Steroid hormone biosynthesis                     8           0.005165
  KEGG_PATHWAY   hsa00982: Drug metabolism                                  9           0.007941
  KEGG_PATHWAY   hsa00591: Linoleic acid metabolism                         6           0.008896
  KEGG_PATHWAY   hsa00340: Histidine metabolism                             6           0.010346
  KEGG_PATHWAY   hsa04115: p53 signaling pathway                            9           0.013645
  KEGG_PATHWAY   hsa00260: Glycine, serine and threonine metabolism         6           0.013718
  KEGG_PATHWAY   hsa00410: β-Alanine metabolism                             5           0.017838
  KEGG_PATHWAY   hsa04920: Adipocytokine signaling pathway                  8           0.036604
  KEGG_PATHWAY   hsa00620: Pyruvate metabolism                              6           0.037809
  KEGG_PATHWAY   hsa00232: Caffeine metabolism                              3           0.039507
  KEGG_PATHWAY   hsa05222: Small cell lung cancer                           9           0.042544
  KEGG_PATHWAY   hsa04512: ECM-receptor interaction                         9           0.042544

DEGs, differentially expressed genes; KEGG, Kyoto Encyclopedia of Genes and Genomes.

[^1]: Contributed equally
